Nino Hallén

Costs of diabetes complications: hospital-based care and absence from work for 392,200 people with type 2 diabetes and matched control participants in Sweden

Emelie Andersson, Sofie Persson, Nino Hallén et al. · Diabetologia · 2020 · 82 citations · Full text

Evaluating the Cost-Effectiveness of Once-Weekly Semaglutide 1 mg Versus Empagliflozin 25 mg for Treatment of Patients with Type 2 Diabetes in the UK Setting

Matthew Capehorn, Nino Hallén, James Baker‐Knight et al. · Diabetes Therapy · 2021 · 23 citations · Full text

Assessing the cost-effectiveness of a once-weekly GLP-1 analogue versus an SGLT-2 inhibitor in the Spanish setting: Once-weekly semaglutide versus empagliflozin

Juan José Gorgojo Martínez, Samuel J. P. Malkin, Virginia Martín et al. · Journal of Medical Economics · 2019 · 19 citations

Evaluation of the Long-Term Cost-Effectiveness of Once-Weekly Semaglutide Versus Dulaglutide and Sitagliptin in the Spanish Setting

Virginia Martín, Josép Vidal, Samuel J. P. Malkin et al. · Advances in Therapy · 2020 · 18 citations · Full text

The Short-Term Cost-Effectiveness of Once-Weekly Semaglutide Versus Once-Daily Sitagliptin and Once-Weekly Dulaglutide for the Treatment of Patients with Type 2 Diabetes: A Cost of Control Analysis in Spain

Josép Vidal, Samuel J. P. Malkin, Barnaby Hunt et al. · Diabetes Therapy · 2020 · 13 citations · Full text